NanoRepro AGHAM:NN6 -2.12%51 Return-on-Tangible-Equity is -4.91% as of Jun. 2025. GuruFocus rates HAM:NN6 with a GF Score™ of 51/100 and a GF Value™ of €1.05 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 193 Medical Diagnostics & Research companies, NanoRepro AG ranks worse than 58.55% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. NanoRepro AG's annualized net income for the quarter that ended in Jun. 2025 was €-1.69 Mil. NanoRepro AG's average shareholder tangible equity for the quarter that ended in Jun. 2025 was €34.36 Mil. Therefore, NanoRepro AG's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2025 was -4.91%.
The historical rank and industry rank for NanoRepro AG's Return-on-Tangible-Equity or its related term are showing as below:
HAM:NN6'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -200.85 Med: -11.08 Max: 90.79
Current: -4.95
During the past 13 years, NanoRepro AG's highest Return-on-Tangible-Equity was 90.79%. The lowest was -200.85%. And the median was -11.08%.
HAM:NN6's Return-on-Tangible-Equity is ranked worse than 58.55% of 193
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.07
vs HAM:NN6: -4.95
NanoRepro AG (HAM:NN6) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
NanoRepro AG Return-on-Tangible-Equity Related Terms
NanoRepro AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for NanoRepro AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:NN6 vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, NanoRepro AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NanoRepro AG Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NanoRepro AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where NanoRepro AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Jun. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -4.91% mean?
NanoRepro AG (HAM:NN6) has a Return-on-Tangible-Equity of -4.91% as of Jun. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NanoRepro AG and its competitors. According to the industry distribution chart, NanoRepro AG ranks #113 out of 193 companies in the Medical Diagnostics & Research industry, placing it in the top 58.5%.
Is NanoRepro AG's Return-on-Tangible-Equity too high?
NanoRepro AG's current Return-on-Tangible-Equity is -4.91%. Based on the distribution chart, NanoRepro AG ranks #113 out of 193 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, NanoRepro AG has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NanoRepro AG's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, NanoRepro AG ranks #113 out of 193 companies for Return-on-Tangible-Equity. This places NanoRepro AG in the lower half of its industry. The industry median Return-on-Tangible-Equity is 0.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.07, based on 193 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on NanoRepro AG and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NanoRepro AG's current Return-on-Tangible-Equity is -4.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NanoRepro AG stock overvalued right now?
Based on GuruFocus' analysis, NanoRepro AG (HAM:NN6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.05, compared to a current price of €2.31 — trading 120% above its estimated fair value. The current Return-on-Tangible-Equity is -4.91%. NanoRepro AG's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For NanoRepro AG (HAM:NN6), the current Return-on-Tangible-Equity is -4.91% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NanoRepro AG (HAM:NN6) Overvalued in 2026?
Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued.
The current stock price of €2.31 is trading 120% above its estimated GF Value™ of €1.05.
GuruFocus considers NanoRepro AG to be Significantly Overvalued.
Key valuation signals for HAM:NN6:
Return-on-Tangible-Equity: -4.91%
GF Value™: €1.05 vs. price of €2.31 (120% above fair value)
No single metric tells the full story. See the HAM:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
51GF Score
Get the complete analysis for HAM:NN6
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:NN6 has been successfully added to your 
